NSE: PFIZER | BSE: 500680

Mid-range Performer

Download real time

5812.00 28.00 (0.48%)

57.04% Gain from 52W Low

54,424 NSE+BSE Volume

NSE 07 Jul, 2025 1:53 PM (IST)

26,588.6

Market Cap

High in industry

0.2

Beta 1Year

Very Low volatility

Dividend

Pfizer Ltd. has an upcoming dividend of ₹35.00 per share due on 09 Jul 2025 See details

Pfizer Ltd. share price target and research reports

Name: Latest research reports of Pfizer Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Pfizer Ltd.
Rating: 4
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for PFIZER, BSE:500680 Pfizer Ltd.

Search Inside the pdf :

Pfizer Ltd.

31 Oct 2023

5812.00

0.48%

Margins balm the pain of a weak season

Accumulate: Pfizer Ltd.

ICICI Securities Limited

Pfizer’s Q2FY24 revenues declined by 9.8%, marred by a weak season for acute products and the recall of three key brands Magnex, Magnamycin and Zoysn. Gross margins contracted 40bps YoY, but recovered 503bps QoQ to 64.4% as the impact of mandated price cuts on NLEM products was partially offset by better product mix.

Pfizer Ltd. has gained 44.67% in the last 3 Months

Pfizer Ltd.

18 Aug 2023

5812.00

0.48%

Earnings hit by product recall

Accumulate: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q1FY24 performance was marred by recall of three key brands - Magnex, Magnamycin and Zoysn. These had annual sales of INR 1.4bn in FY23. Gross margin contracted 420bps YoY at 59.4%, also impacted by mandated price cut on NLEM products.

Number of FII/FPI investors decreased from 151 to 129 in Mar 2025 qtr

Pfizer Ltd.

17 May 2023

5812.00

0.48%

Power brands help restore revenue traction

Accumulate: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Q4FY23 marked a turnaround in Pfizer’s performance as the declining revenue trend (down 7% in FY23) was arrested in Q4, which saw a 4% YoY rise. The turnaround was driven by traction in key brands such as Magnex, Corex DX, Dolonex, Minipress XL and Prevenar-13.

Number of FII/FPI investors decreased from 151 to 129 in Mar 2025 qtr

Pfizer Ltd.

16 May 2023

5812.00

0.48%

Pfizer Ltd

Hold: Pfizer Ltd.

Target

ICICI Direct

Pfizer Ltd. has gained 25.63% in the last 1 Year

Pfizer Ltd.

17 Nov 2022

5812.00

0.48%

Pfizer Ltd

Hold: Pfizer Ltd.

Target

ICICI Direct

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

14 Nov 2022

5812.00

0.48%

Stringent cost controls lift margins

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q2FY23 performance beat our estimates on the profitability front driven by strong control over costs. Revenue was flat YoY (+7.5% QoQ) at Rs6.4bn (I-Sec: Rs.6.4bn).

Pfizer Ltd. has gained 25.63% in the last 1 Year

Pfizer Ltd.

08 Aug 2022

5812.00

0.48%

Cost-control supports margins

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q1FY23 performance beat our estimates on the profitability front driven
by strong control over costs. Revenues declined 20.9% YoY (+7.9% QoQ) to Rs 5.9bn (I-Sec: Rs 5.9bn) on a high covid-led base.